This study evaluates the feasibility, acceptability, and preliminary efficacy of "Forward to Quit" (F2Q), a person-centered mobile health (mHealth) smoking cessation intervention designed specifically for transgender adults. The intervention was developed in collaboration with transgender individuals and gender-affirming healthcare providers. The study includes usability testing and a remote single-arm pilot trial. Primary outcomes include feasibility and acceptability of both the intervention and remote biochemical verification of smoking cessation. Secondary outcomes include self-reported and biochemically verified smoking cessation, as well as changes in psychosocial factors such as social support and gender affirmation. The goal is to inform a future large-scale trial and address tobacco-related health disparities in transgender populations.

Inclusion Criteria:

• Identify with a gender different from sex assigned at birth
• 18+ years of age
• Report smoking at least 5 cigarettes per day
• Have smoked 100+ cigarettes in their lifetime
• Own a device that can access the Internet (e.g., tablet, smartphone)
• Speak English
• Be willing to submit biochemical samples to verify cessation
• Be willing to use a website-based intervention to help with quit attempt
• Be willing to set a quit date within 1 month of baseline assessment
• Be willing to complete 3 months post-baseline and 6 months post-baseline assessments

Exclusion Criteria:

• Do not meet inclusion criteria
• Medical conditions precluding use of the carbon monoxide (CO) monitor or salivary cotinine testing
• Current use of pharmacotherapies for nicotine dependence
• Enrollment in another tobacco cessation program

Unsure of where or how IPD would be shared